Targeted therapy in metastatic colorectal cancer – An example of personalised medicine in action
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
In metastatic colorectal cancer (mCRC), an improved understanding of the underlying pathology and molecular biology has successfully merged with advances in diagnostic techniques and local/systemic therapies as well as improvements in the functioning of multidisciplinary teams, to enable tailored treatment regimens and optimized outcomes. Indeed, as a result of these advancements, median survival for patients with mCRC is now in the range of 20-24months, having approximately tripled in the last 20years. The identification of KRAS as a negative predictive marker for activity of epidermal growth factor receptor (EGFR)-targeted monoclonal antibodies (mAbs), such as panitumumab (Amgen, Thousand Oaks, USA) and cetuximab (ImClone, Branchburg, USA), has perhaps had the greatest impact on patient management. This meant that, for the first time, mCRC patients unlikely to respond to a targeted therapy could be defined ahead of treatment. Ongoing controversies such as whether patients with KRAS G13D- (or BRAF V600-) mutated tumours can still respond to EGFR-targeted mAbs and the potential impact of inter- and intra-tumour heterogeneity on tumour sampling show that the usefulness of KRAS as a biomarker has not yet been exhausted, and that other downstream biomarkers should be considered. Conversely, a predictive biomarker for anti-angiogenic agents such as bevacizumab (Genentech, San Francisco, USA) in the mCRC setting is still lacking. In this review we will discuss the discovery and ongoing investigation into predictive biomarkers for mCRC as well as how recent advances have impacted on clinical practice and ultimately the overall cost of treatment for these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815 · cited 1×
“Chemotherapy has been standard care for mCRC patients for many years, and is based mainly on the use of three agents: 5-fluorouracil (5-FU; APP Pharmaceuticals, Schaumburg, USA), irinotecan (Pfizer, New York, USA)(14,15) and oxaliplatin (Sanofi-Aventis, Bridgewater, USA).(16,17) Infusional 5-FU regimenssuch as FOLFIRI…”
BackgroundDouillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Self-citationSaltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 1×
“Some tumours show intrinsic resistance to bevacizumab and, when they do occur, responses are often transitory with patients showing restoration of tumour growth due to evasive resistance.(43)”
BackgroundGiantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Cited by
Brenner, H., Kloor, M., & Pox, C. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61649-9 · Cited by 2,762
Banerjee, A., Pathak, S., Subramanium, V. D., G., D., Murugesan, R., & Verma, R. S. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.05.006 · Cited by 204
CK1α overexpression correlates with poor survival in colorectal cancer
Richter, J., Kretz, A.-L., Lemke, J., Fauler, M., Werner, J.-U., Paschke, S., Leithäuser, F., Henne-Bruns, D., Hillenbrand, A., & Knippschild, U. (2018) · BMC Cancer · doi:10.1186/s12885-018-4019-0 · Cited by 28
“Recent improvement of the chemotherapeutic regimes supplemented with biological reagents such as EGFR (epidermal growth factor receptor) antagonists have been shown to significantly improve patients’ overall survival [10].”
BackgroundRecent developments in antibody derivatives against colorectal cancer; A review
Ghani, S., Bahrami, S., Rafiee, B., Eyvazi, S., Yarian, F., Ahangarzadeh, S., Khalili, S., Shahzamani, K., Jafarisani, M., Bandehpour, M., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118791 · Cited by 20
Metadata
- Authors
- Heinemann, V., Douillard, J. Y., Ducreux, M., & Peeters, M.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 39
- Issue
- 6
- Pages
- 592-601
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W2045766910
- Cited by
- 120
- References
- 32
- FWCI
- 11.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeted therapy in metastatic colorectal cancer – An example of personalised medicine in action. https://app.cochat.ai/papers/10.1016/j.ctrv.2012.12.011
- The paper
- Heinemann, V., Douillard, J. Y., Ducreux, M., & Peeters, M. (2013). Targeted therapy in metastatic colorectal cancer – An example of personalised medicine in action. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2012.12.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.